Search | Clinical Trials Finder

Conditions: Type 2 Diabetes (T2DM), Cardiovascular Disease
Interventions: Resistance Training, Standard of Care; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions: Orally administered preparation of fecal microbiota (MTP-101P); Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenosis 2, Acid Maltase Deficiency
Interventions: alglucosidase alfa; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 12 Months
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 14
States / cities: Little Rock, Arkansas • Oakland, California • Gainsville, Florida + 11 more

Conditions: Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions: Valproate, Etoposide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mandibular Reconstruction, Segmental Mandibular Defects
Interventions: Surgical Resection and Reconstruction; Procedure
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2022 – 2030
U.S. locations: 5
States / cities: Jacksonville, Florida • Chicago, Illinois • New Hyde Park, New York + 2 more

Conditions: Anxiety
Interventions: +Short AAT, +Long AAT, Active control; NO dog; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 4 Years to 8 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
Interventions: BioFreedom drug coated coronary stent; Device
Lead sponsor: Biosensors Europe SA; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 10 more

Conditions: Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG; Procedure · Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: qualitative interviews with patients, questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: BKR-017; Dietary Supplement
Lead sponsor: BioKier Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina

Conditions: Germ Cell Tumor
Interventions: Zanzalintinib, Etoposide Capsule; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Skin Basal Cell Carcinoma
Interventions: Itraconazole, Placebo; Drug · Other
Lead sponsor: Jean Yuh Tang; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Cemiplimab, Platinum-based chemotherapy, REGN7075; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 15
States / cities: Orange, California • Skokie, Illinois • Detroit, Michigan + 10 more

Conditions: Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions: Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more

Conditions: Rheumatoid Arthritis
Interventions: tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: Educational website; Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Constipation
Interventions: naloxegol; Drug
Lead sponsor: Joseph Ma; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Liver Transplant Recipients
Interventions: Behavioral Telehealth; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions: BMS-986504; Drug
Lead sponsor: Ankit Mangla, MD; Other
Eligibility: 12 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Renal Cell Carcinoma
Interventions: CRLX101, Bevacizumab, Standard of Care (Investigator Choice); Drug
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 38
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more

Conditions: Pain, Anxiety
Interventions: Hand-holding, Stress Ball; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: AVT001, Placebo; Drug · Other
Lead sponsor: Avotres Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Finerenone, Empagliflozin; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Fairhope, Alabama • El Centro, California • Sacramento, California + 5 more

Search by objective public record fields.

The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

Animal Assisted Therapy in Pediatric Dentistry

BioFreedom US IDE Feasibility Trial

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Topical Itraconazole in Treating Patients With Basal Cell Cancer

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Evaluating the Use of an Informational Head and Neck Cancer Website.

Naloxegol in Cancer Opioid-Induced Constipation

Adult Liver Transplant Enhanced Care

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Patient Comfort During Dermatologic Procedures

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)